Opyl Ltd. (AU:OPL) has released an update.
Opyl Limited announced a decrease in FY24 revenue to $397,637, alongside a $3.13 million pre-tax loss, emphasizing strategic shifts like the launch of their AI clinical trial platform, TrialKey. The company secured its first TrialKey contract and pursued new growth avenues, including a partnership aiming at a $100 million AI Biotech Fund. Despite the revenue dip due to strategic divestment, Opyl is poised for future growth with innovative AI solutions in the clinical trial market.
For further insights into AU:OPL stock, check out TipRanks’ Stock Analysis page.